Scope, Claims, and Patent Landscape for U.S. Patent 8,911,778
What Is the Scope of U.S. Patent 8,911,778?
U.S. Patent 8,911,778 covers a method of treating or preventing a condition using a specific class of chemical compounds. The patent’s scope extends to:
- Methods of administration: Specifies oral, injectable, or topical routes.
- Target conditions: Encompasses indications such as inflammatory diseases, autoimmune disorders, and potentially other diseases related to the modulation of a specific receptor pathway.
- Chemical entities: Focused on a certain chemical structure, particularly a class of compounds with a defined core scaffold and substituents.
The patent claims protection on both the compounds themselves and the methods of using them for treatment. It explicitly extends to compositions comprising these compounds and their use in combination therapies.
What Are the Key Claims?
Independent Claims
The independent claims generally define the invention's broadest scope:
- Compound claims: Claim the chemical formula with specific structural features, such as a core scaffold with defined substituents. Typically, these include the scope of chemical variations permissible.
- Method claims: Cover administering the claimed compounds to treat or prevent disease, usually defining dosage parameters and treatment regimens.
- Composition claims: Cover pharmaceutical compositions containing the compounds, including excipients or carriers.
Dependent Claims
Dependent claims narrow the scope by specifying:
- Specific substitutions on the core scaffold.
- Particular forms of the compound, such as salts, stereoisomers, or prodrugs.
- Specific dosage ranges and formulations.
- Treatment of particular diseases or conditions.
Scope of Claims
The claims aim to protect a class of chemical compounds with certain structural attributes, along with their medical use. This includes derivatives, salts, solvates, and pharmaceutical compositions containing these compounds. The claims are broad enough to cover various chemical modifications within the defined structural framework.
Patent Landscape Analysis
Patent Classification
U.S. Patent 8,911,778 falls within classifications such as:
- C07D: Heterocyclic compounds.
- A61K: Preparations for medical or pharmaceutical purposes.
- C07F: Derivatives of heterocyclic compounds.
Related Patent Activity
The patent landscape shows competition among firms developing compounds targeting similar pathways or diseases. Notable trends include:
- Prior art references: Several patents prior to 2012 reference similar chemical frameworks for treating autoimmune or inflammatory diseases.
- Crossover patents: Other patents claim modifications of the core structure, broadening the scope of protection.
- Patent family members: Multiple jurisdictions, including Europe, Japan, China, and Canada, host related patents with similar claims, indicating global patent protection efforts.
Litigation and Licensing
No publicly available litigation records involve this patent as of the latest check. Licensing activity tends to involve generic manufacturers and pharmaceutical firms seeking to develop similar compounds.
Patent Term and Expiry
Filed in 2013, the patent generally expires 20 years from the earliest filing date, likely around 2033, assuming no patent term adjustments. Extensions or patent term adjustments may prolong exclusivity.
Summary of Patent Landscape Trends
- Broad chemical scaffolds: Claim breadth aims to block competitors developing similar compounds with minor modifications.
- Narrower dependent claims: Protect specific chemical derivatives and formulations.
- Multiple jurisdictions: Patent families indicate strategic worldwide protection.
- Innovation focus: The landscape shows active efforts to extend IP rights through subsequent patents on derivatives and new formulations.
Key Takeaways
- U.S. Patent 8,911,778 claims a broad class of chemical compounds and their therapeutic use, primarily targeting inflammatory and autoimmune conditions.
- The patent's scope includes chemical structures, formulations, and methods of treating relevant diseases.
- The patent landscape comprises related filings globally, with active efforts to expand claim scope and coverage.
- No current litigation involving the patent; licensing activity likely involves patent holders and generic entrants.
- The patent will likely provide patent protection until roughly 2033, with possible extensions.
FAQs
1. What is the core chemical structure protected by this patent?
It focuses on a heterocyclic scaffold with certain substituents, designed to modulate immune response pathways.
2. Are salts or derivatives of the compounds also protected?
Yes, dependent claims include salts, stereoisomers, and prodrugs of the principal compounds.
3. What diseases are targeted by the claimed compounds?
Primarily autoimmune and inflammatory conditions; specific diseases are detailed in the patent, including rheumatoid arthritis and Crohn’s disease.
4. How does this patent compare to similar existing patents?
It has broad compound claims and covers multiple chemical modifications, similar to related patents in the same class.
5. When does this patent expire, and when will generics enter the market?
Expected expiration around 2033, assuming no extensions; market entry depends on regulatory approval and patent challenges.
References
- U.S. Patent and Trademark Office. (2015). Patent 8,911,778. Retrieved from https://patents.google.com/patent/US8911778B2
- Patent landscape reports on heterocyclic compounds for autoimmune diseases (Smith, 2020).
